Piqray (alpelisib), Novartis’s new and much-touted medicine for the treatment of HR+/HER2- advanced breast cancer with a PIK3CA mutation, has been approved in Europe but its use has been restricted to an earlier setting than in markets such as the US where the potential blockbuster is already on the market and doing well commercially.
Whereas the wording of the proposed indication for Piqray in the EU covered patients previously treated with CDK 4/6 inhibitors, the authorized indication excludes those patients and is limited to...